Position in DNLI
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,162,389
+$518,004 QoQ
Shares Held
45,194
+15.8% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#119
of 290 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Savvy Advisors, Inc. holds $15,273,481 across 10 Biotechnology names. DNLI ranks #3 (7.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VIR |
Vir Biotechnology, Inc.
|
1,040,665 | $10,604,376 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,185 | $1,362,434 | |
| 3 | DNLI |
Denali Therapeutics Inc.
This page
|
45,194 | $1,162,389 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,881 | $934,349 | |
| 5 | INCY |
Incyte Corp
|
5,248 | $594,913 | |
| 6 | AGIO |
Agios Pharmaceuticals, Inc.
|
6,794 | $252,125 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
5,290 | $206,362 | |
| 8 | CRVO |
CervoMed Inc.
|
25,922 | $80,358 |
All Filings in DNLI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,162,389 | 45,194 | Shares | Sole | 2026-08-03 | |
| 2025-12-31 | $644,385 | 39,030 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $1,119,390 | 77,093 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $1,368,124 | 97,793 | Shares | Sole | 2025-08-04 | |
| No filing history on record for this holder in this stock. | ||||||